Neoadjuvant chemotherapy in the management of colorectal metastases: A review of the literature

Annals of the Academy of Medicine Singapore

Volumn 32, Issue 2, 2003, Pages 205-211

  Ong, Simon Y K ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Chronomodulated; Downstaging; Hepatectomy; Oxaliplatin; Preoperative chemotherapy

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CHRONOTHERAPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG METABOLISM; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LIVER RESECTION; MEDLINE; RELAPSE; REVIEW; SURVIVAL RATE;

EID: 0037820388     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Fong Y, Kemeny N, Paty P, Blumgart L H, Cohen A M. Treatment of colorectal cancer: hepatic metastasis. Semin Surg Oncol 1996; 12: 219-52.
2. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77:1241-6.
3. Steele G Jr, Ravikumar T S. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989; 210:127-38.
4. Cromheecke M, de Jong K P, Hoekstra H J. Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol 1999; 25:451-63.
5. Stangl R, Altendorf-Hofmann A, Charnley R M, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343:1405-10.
6. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1992; 10:904-11.
7. Scheithauer W, Rosen H, Kornek G V, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306:752-5.
8. Poon M A, O'Connell M J, Wieand H S, Krook J E, Gerstner J B, Tschetter L K, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9:1967-72.
9. Borner M M, Castiglione M, Bacchi M, Weber W, Herrmann R, Fey M F, et al. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1998; 9:535-41.
10. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10:896-903.
11. Sugarbaker P H. Metastatic inefficiency: the scientific basis for resection of liver metastases from colorectal cancer. J Surg Oncol Suppl 1993; 3:158-60.
12. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509-20; discussion 520-2.
13. Adson M A. Resection of liver metastases - when is it worthwhile? World J Surg 1987; 11:511-20.
14. Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzetti F. One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 1991; 78:797-801.
15. Cady B, Monson D O, Swinton N W, Survival of patients after colonic resection for carcinoma with simultaneous liver metastases. Surg Gynecol Obstet 1970; 131:697-700.
16. Fortner J G, Silva J S, Golbey R B, Cox E B, Maclean B J. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg 1984; 199:306-16.
17. Adson M A, van Heerden J A, Adson M H, Wagner J S, Ilstrup D M. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984; 119:647-51.
18. Hughes K S, Rosenstein R B, Songhorabodi S, Adson M A, Ilstrup D M, Fortner J G, et al. Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum 1988; 31:1-4.
19. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59-71.
20. Fong Y, Cohen A M, Fortner J G, Enker W E, Turnbull A D, Coit D G, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938-46.
21. Nordlinger B, Vaillant J C, Guiguet M, Balladur P, Paris F, Bachellier P, et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 1994; 12:1491-6.
22. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8:347-53.
23. Nordlinger B, Guiguet M, Vaillant J C, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77:1254-62.
24. Jaeck D, Bachellier P, Guiguet M, Boudjema K, Vaillant J C, Balladur P, et al. Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 1997; 84: 977-80.
25. Jamison R L, Donohue J H, Nagorney D M, Rosen C B, Harmsen W S, Ilstrup D M, Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997; 132:505-10; discussion 511.
26. Elias D, Cavalcanti A, Sabourin J C, Lassau N, Pignon J P, Ducreux M, et al. Resection of liver metastases from colorectal cancer: the real impact of the surgical margin. Eur J Surg Oncol 1998; 24:174-9.
27. Fong Y, Fortner J, Sun R L, Brennan M F, Blumgart L H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-18; discussion 318-21.
28. Taylor M, Forster J, Langer B, Taylor B R, Greig P D, Mahut C. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg 1997; 173:467-71.
29. Rees M, Plant G, Bygrave S. Late results justify resection for multiple hepatic metastases from colorectal cancer. Br J Surg 1997; 84:1136-40.
30. Saltz L B, Cox J V, Blanke C, Rosen L S, Fehrenbacher L, Moore M J, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-14.
31. Douillard J Y, Cunningham D, Roth A D, Navarro M, James R D, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-7.
32. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47.
33. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-47.
34. Garcia-Sainz M, Halberg F. Mitotic rythms in human cancer, reevaluated by electronic computer programs. Evidence for chronopathology. J Natl Cancer Inst 1966; 37:279-92.
35. Levi F A, Zidani R, Vannetzel J M, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86:1608-17.
36. Levi F, Zidani R, Misset J L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997; 350:681-6.
37. Adam R, Bismuth H, Castaing D, Waechter F, Navarro F, Abascal A, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997; 225:51-60; discussion 60-2.
38. Petrowsky H, Gonen M, Jarnagin W, Lorenz M, DeMatteo R, Heinrich S, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235:863-71.
39. Fong Y, Blumgart L H, Cohen A, Fortner J, Brennan M F. Repeat hepatic resections for metastatic colorectal cancer. Ann Surg 1994; 220:657-62.
40. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663-9.
41. Alberts S R, Horvath W L, Donohue J H, Sternfeld W, Goldberg R M, Mahoney M R, et al. Oxaliplatin, 5-Fluorouracil, and Leucovorin for Patients with Liver Only Metastases from Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study. Proceedings of the American Society of Clinical Oncology 2001; 20:abst 511.
42. Tournigand C, Louvet C, Quinaux E, Andre T, Lledo G, Flesch M, et al. FOLFIRI Followed by FOLFOX Versus FOLFOX Followed by FOLFIRI in Metastatic Colorectal Cancer: Final Results of a Phase III Study. Proceedings of the American Society of Clinical Oncology 2001; 20:abst 494.
43. Artru P, Taieb J, Tournigand C, Louvet C, Hafraoui S, Paye F, et al. FOLFOX 7/FOLFIRI (MIROX) regimen as neoadjuvant chemotherapy for patients with resectable metastatic colorectal cancer: preliminary results. Proceedings of the American Society of Clinical Oncology 2002; 21:abst 672.
44. Grage T B, Vassilopoulos P P, Shingleton W W, Jubert A V, Elias E G, Aust J B, et al. Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: A Central Oncology Group study. Surgery 1979; 86:550-5.
45. Chang A E, Schneider P D, Sugarbaker P H, Simpson C, Culnane M, Steinberg S M. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206:685-93.
46. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107:459-65.
47. Hohn D C, Stagg R J, Friedman M A, Hannigan J F Jr, Rayner A, Ignoffo R J, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989; 7:1646-54.
48. Martin J K Jr, O'Connell M J, Wieand H S, Fitzgibbons R J Jr, Mailliard J A, Rubin J, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125:1022-7.
49. Rougier P, Laplanche A, Huguier M, Hay J M, Ollivier J M, Escat J, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10:1112-8.
50. Allen-Mersh T G, Glover C, Fordy C, Mathur P, Quinn H. Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastases. Eur J Surg Oncol 2000; 26:468-73.
51. Allen-Mersh T G, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344:1255-60.
52. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996; 88:252-8.
53. Harmantas A, Rotstein L E, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 1996; 78:1639-45.
54. Lorenz M, Muller H H. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial of intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18:243-54.
55. Clavien P A, Selzner N, Morse M, Selzner M, Paulson E. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002; 131:433-42.
56. Meric F, Patt Y Z, Curley S A, Chase J, Roh M S, Vauthey J N, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000; 7:490-5.
57. Elias D, Lasser P, Rougier P, Ducreux M, Bognel C, Roche A. [Major hepatectomy after intra-arterial chemotherapy for initially unresectable liver tumors. Frequency, technical problems, results and indications]. Ann Chir 1996; 50:130-8.
58. Nicholls C, Cassidy J, Freemantle N, Harrison M, Carita P. Cost-effectiveness of oxaliplatin in combination with 5-FU/LV compared with 5-FU/LV alone. J Med Econ 2001; 4:127-35.
59. Nicholls C, Cassidy J, Freemantle N, Harrison M, Carita P. Cost-effectiveness of combination chemotherapy (oxaliplatin or irinotecan in combination with 5-FU/LV) compared to 5-FU/LV alone. J Med Econ 2001; 4:115-25.
60. Poston G, Benjamin I S, Diamond T, Finch-Jones M, Parks R W, Primrose J N, et al. Costs of neoadjuvant chemotherapy and surgery in patients with liver metastases from advanced colorectal cancer. J Med Econ 2001; 4:167-77.
61. Kemeny N, Huang Y, Cohen A M, Shi W, Conti J A, Brennan M F, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-48.
62. Kemeny M M, Adak S, Gray B, Macdonald J S, Smith T, Lipsitz S, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study. J Clin Oncol 2002; 20:1499-505.